Preview

Вестник дерматологии и венерологии

Расширенный поиск

Лечение больных крапивницей блокатором H1 гистаминовых рецепторов рупатадином

https://doi.org/10.25208/0042-4609-2014-0-3-116-120

Полный текст:

Аннотация

Основное место в терапии больных крапивницей занимают антигистаминные препараты второго поколения, однако они эффективны лишь у 45-60% пациентов. Это требует разработки и внедрения новых средств терапии больных крапивницей, одним из которых является рупатадин - антигистаминный препарат второго поколения. Одновременно рупатадин обладает выраженной способностью блокировать воспалительное действие тромбоцитактивирующего фактора. Благодаря своему двойному эффекту рупатадин в дозе 10 мг 1 раз в день для перорального приема является эффективным средством терапии крапивницы, безопасность которого подтверждена в клинических исследованиях.

Об авторах

А. А. Кубанов
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


В. В. Чикин
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


Список литературы

1. Zuberbier T., Asero R., Bindslev-Jensen C. et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426. Литература

2. Clive E.H., Ruth A., Malcom W. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645-657.

3. Baiardini I., Giardini A., Pasquali M. et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58 (7): 621-623.

4. Reeves G.E., Boyle M.J., Bonfield J. et al. Impact of hydroxychloroquine therapy on chronic urticaria: Chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34: 182-186. 120 к № 3, 2014

5. Staubach P., Eckhardt-Henn A., Dechene M. et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294-298.

6. Uguz F., Engin B., Yilmaz E. Quality of life in patients with chronic idiopathic urticaria: The impact of Axis I and Axis II psychiatric disorders. Gen Hosp Psychiatry 2008; 30: 453-457.

7. O’Donnell B.F., Lawlor F., Simpson J. et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136 (2): 197-201.

8. Kaplan A.P., Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39 (6): 777-787.

9. Zuberbier T., Asero R., Bindslev-Jensen C. et al. EAACI/GA2LEN/ EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.

10. Makris M., Maurer M., Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert Opin Pharmacother 2013; 14 (18): 2511-2519.

11. Leurs R., Church M.K., Taglialatela M. H1-antihista-mines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-498.

12. Kim H., Lynde C. Impact of desloratadine on symptoms and quality of life in subjects with chronic idiopathic urticaria: a multicenter, practice-based study. Arch Drug Inf 2008; 1 (2): 63-69.

13. Kolasani B.P., Mudium R., Reddy N. A comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria. As J Biomed Pharm Sci 2013; 3 (21): 42-47.

14. Grzelewska-Rzymowska I., Gôrski P. Rupatadine: a novel second-generation antihistamine. Post Dermatol Alergol 2011; XXVIII, 6: 480-488.

15. Kaplan A.P. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012; 4 (6): 326-331.

16. Curtin M.L. Current status of platelet activating factor antagonists. Exp Opin Ther Patents 1998; 8: 703-711.

17. Kajiwara N., Sasaki T., Bradding P. et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol 2010; 125: 1137-1145.

18. Yost C.C., Weyrich A.S., Zimmerman G.A. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010; 92 (6): 692-697.

19. Hasan A.M., Mourtada-Maarabouni M., Hameed M.S. et al. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol 2010; 9: 1017-1021.

20. Marques S.A., Dy L.C., Southall M.D. et al. The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J Pharmacol Exp Ther 2002; 300: 1026-1035.

21. Krause K., Gimenez-Arnau A., Martinez-Escala E. et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy 2013; 68: 256-258.

22. Thomas G., Church M.K. Platelet activating factor does not release histamine from human dispersed cutaneous mast cells. Clin Exp Allergy 1990; 20: 377-382.

23. Katayama I., Matsui S., Murota H. Platelet activation as a possible indicator of disease activity in chronic urticaria: link with blood coagulation and mast cell degranulation. J Clin Exp Dermatol Res 2013; 4: 194. doi: 10.4172/2155-9554.1000194.

24. Asero R., Tedeschi A., Riboldi P., Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-1117.

25. Rajappa M., Chandrashekar L., Sundar I. et al. Platelet oxidative stress and systemic inflammation in chronic spontaneous urticaria. Clin Chem Lab Med 2013; 51: 1789-1794.

26. Takahagi S., Mihara S., Iwamoto K. et al. Coagulation/ fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65: 649-656.

27. Merlos M., Giral M., Balsa D. et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF) J Pharmacol Exp Ther 1997; 280 (1): 114-121.

28. Maiti R., Jaida J., Raghavendra B. et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol 2011; 10 (12): 1444-1450.

29. Izquierdo I., Nieto C., Ramis J. et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Methods Find Exp Clin Pharmacol 1997; 19 (Suppl. A): 189-203.

30. Queralt M., Merlos M., Giral M., Puigdemont A. Dual effect of rupatadine on edema induced by PAF and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Develop Res 1996; 39: 12-18.

31. Church M.K. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine-and PAF-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010; 163: 1330-1332.

32. Izquierdo I., Merlos M., Garcia-Rafanell J. Rupatadine, a new selective histamine HI receptor and platelet activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003; 39: 451-468.

33. Queralt M., Brazis P., Merlos M. et al. In vitro inhibitory effect of rupatadine on histamine and TNF-a release from dispersed canine skin mast cells and the human cell line HMC-1. Inflam Res 2000; 49: 355-360.

34. Vasiadi M., Kalogeromitros D., Kempuraj D. et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol 2010; 151 (1): 38-45.

35. Alevizos M., Karagkouni A., Vasiadi M. et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol 2013; 111 (6): 542-547.

36. Dubertret L., Zalupca L., Cristodoulo T. et al. Once daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007; 17: 223-228.

37. Mullol J., Bousquet J., Bachert C. et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008; 63 (Suppl 87): 5-28.

38. Giménez-Arnau A., Izquierdo I., Maurer M. The use of a responder analyses to identify clinically meaningful differences in chronic urticaria patients following placebocontrolled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venerol 2009; 23: 1088-1091.

39. Keam S.J., Plosker G.L. Rupatadine: a review of its use in the management of allergic disorders. Drug 2007; 67 (3): 457-474.

40. Caballero R., Valenzuela C., Longobardo M. et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol 1999; 128: 1071-1081.

41. Barbanoj M.J., Garcia-Gea C., Morte A. et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004; 50: 311-321.

42. Vuurman E., Theunissen E., van Oers A. et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacol Clin Exp 2007; 22: 289-297.

43. Saint-Martin F., Dumur J.P., Perez I., Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and HI receptor specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004; 14: 34-40.

44. Guadano E.M., Serra-Batlles J., Meseguer J. et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004; 59: 766-771.

45. Martinez-Cocera C., De Molina M., Marti-Guadano E. et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J lnvestig Allergol Clin Immunol 2005; 15: 22-29.

46. Maiti R., Rahman J., Jaida J. et al. Rupatadine and levocetirizine for seasonal allergic rhinitis. A comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010; 136: 796-800.

47. Valero A., de la Torre F., Castillo J.A. et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis. A multicentre, open-label study in Spain. Drug Safety 2009; 32: 33-42.


Для цитирования:


Кубанов А.А., Чикин В.В. Лечение больных крапивницей блокатором H1 гистаминовых рецепторов рупатадином. Вестник дерматологии и венерологии. 2014;(3):116-120. https://doi.org/10.25208/0042-4609-2014-0-3-116-120

For citation:


Kubanov A.A., Chikin V.V. The benefit of H2 receptors antagonist Rupatadine in treatment for urticaria. Vestnik dermatologii i venerologii. 2014;(3):116-120. (In Russ.) https://doi.org/10.25208/0042-4609-2014-0-3-116-120

Просмотров: 81


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0042-4609 (Print)
ISSN 2313-6294 (Online)